Varenicline for Smoking Cessation in Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
OBJECTIVE: Virtually no clinical trials for smoking cessation have been undertaken in bipolar disorder. Varenicline has shown efficacy for smoking cessation, but warnings about neuropsychiatric adverse events have been issued. We assessed the efficacy and safety of varenicline in euthymic bipolar subjects motivated to quit smoking. METHOD: Clinically stable adult patients with DSM-IV bipolar disorder (n = 60) who smoked ≥ 10 cigarettes per day were randomized to a 3-month, double-blind, placebo-controlled varenicline trial and a 3-month follow-up. Study enrollment was completed from February 2010 through March 2013. Varenicline was dosed using standard titration, and smoking cessation counseling was provided to all patients. The primary outcome was defined as a 7-day point prevalence of self-reported no smoking verified by expired carbon monoxide level < 10 ppm at 12 weeks. Psychopathology and side-effects were assessed at each visit. RESULTS: At 3 months (end of treatment), significantly more subjects quit smoking with varenicline (n/n = 15/31, 48.4%) than with placebo (n/n = 3/29, 10.3%) (OR = 8.1; 95% CI, 2.03-32.5; P < .002). At 6 months, 6 of 31 varenicline-treated subjects (19.4%) remained abstinent compared to 2 of 29 (6.90%) assigned to placebo (OR = 3.2; 95% CI, 0.60-17.6; P = .17). Psychopathology scores remained stable. Ten serious adverse events occurred (n = 6, varenicline; n = 4, placebo). Abnormal dreams occurred significantly more often in varenicline-treated subjects (n/n = 18/31, 61.3%) than in those receiving placebo (n/n = 9/29, 31%; Fisher exact test, P = .04). Eight varenicline-treated and 5 placebo-assigned subjects expressed fleeting suicidal ideation, a nonsignificant difference. CONCLUSIONS: Varenicline shows efficacy for initiating smoking cessation in bipolar patients, but medication trials of longer duration are warranted for maintaining abstinence. Vigilance for neuropsychiatric adverse events is prudent when initiating varenicline for smoking cessation in this patient population. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01010204.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Six of eight published studies focused on smoking cessation for people with BD have sample sizes of twenty or less”
From Smokers with bipolar disorder, other affective disorders, and no mental health conditions: Comparison of baseline characteristics and success at quitting in a large 12-month behavioral intervention randomized trial. (2018) · cites this paper as Chengappa et al., 2014
In the citing paper
“All studies were in favor of the specific treatment.”
From The detrimental effects of smoking on the course and outcome in adults with bipolar disorder—A narrative review (2023) · cites this paper as [73]
In the citing paper
“We identified only four published smoking cessation treatment trials in smokers with BD: one very small open pilot study with bupropion (70), two open pilot studies with varenicline (71, 72), and 2 studies using varenicline either alone (73) or in combination with CBT (74).”
From The detrimental effects of smoking on the course and outcome in adults with bipolar disorder—A narrative review (2023) · cites this paper as [73]
Citations
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“A variety of strategies may be employed including supportive programmes (telephone, group), nicotine supplements and varenicline (Chengappa et al., 2014; Evins et al., 2014).”
BackgroundNicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Smoking cessation for improving mental health
Taylor, G. M., Lindson, N., Farley, A., Leinberger-Jabari, A., Sawyer, K., te Water Naudé, R., Theodoulou, A., King, N., Burke, C., & Aveyard, P. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013522.pub2 · Cited by 266
Cigarette Smoking by Patients With Serious Mental Illness, 1999–2016: An Increasing Disparity
Dickerson, F., Schroeder, J., Katsafanas, E., Khushalani, S., Origoni, A. E., Savage, C., Schweinfurth, L., Stallings, C. R., Sweeney, K., & Yolken, R. H. (2018) · Psychiatric Services · doi:10.1176/appi.ps.201700118 · Cited by 190
Peckham, E., Brabyn, S., Cook, L., Tew, G., & Gilbody, S. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1419-7 · Cited by 169
“Of these six trials, four tested varenicline plus smoking cessation counselling versus placebo plus counselling [30, 31, 35, 37], one tested varenicline plus group therapy versus placebo plus group therapy [25], and one tested varenicline versus placebo [27].”
BackgroundSmoking cessation and reduction in people with chronic mental illness
Tidey, J. W., & Miller, M. E. (2015) · BMJ · doi:10.1136/bmj.h4065 · Cited by 166
Thomas, K. H., Martin, R. M., Knipe, D. W., Higgins, J. P. T., & Gunnell, D. (2015) · BMJ · doi:10.1136/bmj.h1109 · Cited by 155
Thomas, K. H., Dalili, M. N., López-López, J. A., Keeney, E., Phillippo, D., Munafo, M. R., Stevenson, M., Caldwell, D. M., & Welton, N. J. (2021) · Health Technology Assessment · doi:10.3310/hta25590 · Cited by 171
Jackson, J. G., Diaz, F. J., Lopez, L., & de Leon, J. (2015) · Bipolar Disorders · doi:10.1111/bdi.12319 · Cited by 120
Roberts, E., Eden Evins, A., McNeill, A., & Robson, D. (2016) · Addiction · doi:10.1111/add.13236 · Cited by 119
“Nine trials were conducted in participants with a diagnosis of schizophrenia or schizoaffective disorder [43,46–50,52,55,56,58,59], two trials in participants with a diagnosis of schizophrenia [44,45,57] and three trials were conducted in participants with a diagnosis of bipolar affective disorder [50,52,53].”
BackgroundCancer screening, prevention, and treatment in people with mental illness
Weinstein, L. C., Stefančić, A., Cunningham, A., Hurley, K. E., Cabassa, L. J., & Wender, R. C. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21334 · Cited by 121
Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations
Cather, C., Pachas, G. N., Cieslak, K. M., & Evins, A. E. (2017) · CNS Drugs · doi:10.1007/s40263-017-0438-8 · Cited by 115
Nicotine receptor partial agonists for smoking cessation
Livingstone‐Banks, J., Fanshawe, T. R., Thomas, K. H., Theodoulou, A., Hajizadeh, A., Hartman, L., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub8 · Cited by 168
Evins, A. E., Benowitz, N. L., West, R., Russ, C., McRae, T., Lawrence, D., Krishen, A., St Aubin, L., Maravic, M. C., & Anthenelli, R. M. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001015 · Cited by 98
Interventions for preventing weight gain after smoking cessation
Hartmann-Boyce, J., Theodoulou, A., Farley, A., Hajek, P., Lycett, D., Jones, L. L., Kudlek, L., Heath, L., Hajizadeh, A., Schenkels, M., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006219.pub4 · Cited by 94
Evins, A. E., Cather, C., & Laffer, A. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000063 · Cited by 85
Reid, R. D., Pritchard, G., Walker, K. L., Aitken, D., Mullen, K., & Pipe, A. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.151510 · Cited by 78
Sterling, L. H., Windle, S. B., Filion, K. B., Touma, L., & Eisenberg, M. J. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002849 · Cited by 70
Nicotine receptor partial agonists for smoking cessation
Livingstone‐Banks, J., Fanshawe, T. R., Thomas, K. H., Theodoulou, A., Hajizadeh, A., Hartman, L., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub9 · Cited by 81
Tonstad, S., Arons, C., Rollema, H., Berlin, I., Hájek, P., Fagerström, K. O., Els, C., McRae, T. D., & Russ, C. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1729708 · Cited by 71
Molero, Y., Lichtenstein, P., Zetterqvist, J., Gumpert, C. H., & Fazel, S. (2015) · BMJ · doi:10.1136/bmj.h2388 · Cited by 54
Smoking Use and Cessation Among People with Serious Mental Illness.
Annamalai, A., Singh, N., & O’Malley, S. S. (2015) · PubMed Central · Cited by 58
Heffner, J. L., Kelly, M. M., Waxmonsky, J., Mattocks, K., Serfozo, E., Bricker, J. B., Mull, K. E., Watson, N. L., & Ostacher, M. (2020) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntz242 · Cited by 39
Wu, Q., Gilbody, S., Peckham, E., Brabyn, S., & Parrott, S. (2016) · Addiction · doi:10.1111/add.13415 · Cited by 39
Clinical management of comorbid diabetes and psychotic disorders
Chwastiak, L., Freudenreich, O., Tek, C., McKibbin, C. L., Han, J., McCarron, R. M., & Wisse, B. E. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00105-4 · Cited by 40
Pharmacotherapies for co‐occurring substance use and bipolar disorders: A systematic review
Coles, A. S., Sasiadek, J., & George, T. P. (2019) · Bipolar Disorders · doi:10.1111/bdi.12794 · Cited by 39
Self-citationLoreto, A. R., Carvalho, C. F. C., Frallonardo, F. P., Ismael, F., de Andrade, A. G., & Castaldelli-Maia, J. M. (2017) · Journal of Dual Diagnosis · doi:10.1080/15504263.2017.1328149 · Cited by 34
Pearsall, R., Smith, D. J., & Geddes, J. R. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027389 · Cited by 30
García‐Portilla, M. P., García-Álvarez, L., Sarramea, F., Galván, G., Díaz-Mesa, E., Bobes-Bascarán, T., Al‐Halabí, S., Elizagárate, E., García, C. I., Sáiz, P. A., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.05.011 · Cited by 30
Brody, A. L., Zorick, T., Hubert, R., Hellemann, G. S., Balali, S., Kawasaki, S. S., Garcia, L. Y., Enoki, R., Abraham, P., Young, P., et al. (2017) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntw190 · Cited by 25
Castaldelli-Maia, J. M., Loreto, A. R., Guimarães-Pereira, B. B. S., Carvalho, C. F. C., Gil, F., Frallonardo, F. P., Ismael, F., de Andrade, A. G., Ventriglio, A., Richter, K. P., et al. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.02.005 · Cited by 26
Heffner, J. L., McClure, J. B., Mull, K. E., Anthenelli, R. M., & Bricker, J. B. (2015) · Bipolar Disorders · doi:10.1111/bdi.12300 · Cited by 24
Pharmacotherapy for smoking cessation in schizophrenia: a systematic review
Kozak, K., & George, T. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1721466 · Cited by 26
Self-citationHeffner, J. L., Evins, A. E., Russ, C., Lawrence, D., Ayers, C. R., McRae, T., Aubin, L. S., Krishen, A., West, R., & Anthenelli, R. M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.06.008 · Cited by 23
Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review
Saccaro, L. F., Aimo, A., Panichella, G., & Sentissi, O. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1343427 · Cited by 32
Effective Cessation Strategies for Smokers with Schizophrenia
Evins, A. E., & Cather, C. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.08.001 · Cited by 24
Evins, A. E., Cather, C., Maravić, M. C., Reyering, S., Pachas, G. N., Thorndike, A. N., Levy, D. E., Fung, V., Fischer, M. A., Schnitzer, K., et al. (2022) · Psychiatric Services · doi:10.1176/appi.ps.20220187 · Cited by 22
Cather, C., Hoeppner, S. S., Pachas, G. N., Pratt, S., Achtyes, E. D., Cieslak, K. M., & Evins, A. E. (2017) · Journal of Dual Diagnosis · doi:10.1080/15504263.2017.1319585 · Cited by 21
Perkins, K. A., Chengappa, K. N. R., Karelitz, J. L., Boldry, M. C., Michael, V., Herb, T., Gannon, J. M., Brar, J. S., Ford, L., Rassnick, S., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.292 · Cited by 21
Self-citationEvins, A. E., Hoeppner, S. S., Schoenfeld, D., Hoeppner, B. B., Cather, C., Pachas, G. N., Cieslak, K. M., & Maravić, M. C. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.018 · Cited by 21
Cunningham, F. E., Hur, K., Dong, D., Miller, D. R., Zhang, R., Wei, X., McCarren, M., Mosholder, A. D., Graham, D. J., Aspinall, S. L., et al. (2016) · Addiction · doi:10.1111/add.13329 · Cited by 22
Shah, D., Shah, A., Tan, X., & Sambamoorthi, U. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.03.021 · Cited by 20
Bullen, C., Verbiest, M. E. A., Galea, S., Kurdziel, T., Laking, G. R., Newcombe, D. A. L., Parag, V., & Walker, N. K. (2018) · BMC Public Health · doi:10.1186/s12889-018-5351-7 · Cited by 21
Icick, R., Gard, S., Barde, M., Carminati, M., Desage, A., Guillaume, S., Scott, J. L., & Bellivier, F. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.022 · Cited by 22
Love-Koh, J., Pennington, B., Owen, L., Taylor, M. J., & Griffin, S. C. (2020) · Social Science & Medicine · doi:10.1016/j.socscimed.2020.113339 · Cited by 15
Karelitz, J. L., McClure, E. A., Wolford‐Clevenger, C., Pacek, L. R., & Cropsey, K. L. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108570 · Cited by 16
Schuster, R. M., Cather, C., Pachas, G. N., Zhang, H., Cieslak, K. M., Hoeppner, S. S., Schoenfeld, D., & Evins, A. E. (2017) · Addictive Behaviors · doi:10.1016/j.addbeh.2017.02.028 · Cited by 17
Daumit, G. L., Evins, A. E., Cather, C., Dalcin, A. T., Dickerson, F. B., Miller, E. R., Appel, L. J., Jerome, G. J., McCann, U., Ford, D. E., et al. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.1691 · Cited by 13
The safety of treatments for tobacco use disorder
Little, M. A., & Ebbert, J. O. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1131817 · Cited by 16
Tobacco dependence treatment for special populations: challenges and opportunities
Castaldelli-Maia, J. M., Harutyunyan, A., Herbeć, A., Kessel, T., Odukoya, O. O., Kemper, K. E., Hays, J. T., & Vardavas, C. I. (2021) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0782 · Cited by 14
Heffner, J. L., Mull, K. E., Watson, N. L., McClure, J. B., & Bricker, J. B. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.08.034 · Cited by 11
Grunze, A., Mosolov, S., Grunze, H., & Born, C. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1114432 · Cited by 11
Setting the stage to quit smoking in Bipolar Disorder patients: brief advice in clinical practice
Sarramea, F., Jaén‐Moreno, M. J., Balanzá‐Martínez, V., Osuna, M. I., Alcalá, J. Á., Montiel, F. J., Gómez, C., Sánchez, M. D., Rico, A. B., Redondo-Écija, J., et al. (2018) · Adicciones · doi:10.20882/adicciones.1006 · Cited by 12
Heffner, J. L., Watson, N. L., McClure, J. B., Anthenelli, R. M., Hohl, S. D., & Bricker, J. B. (2018) · Journal of Dual Diagnosis · doi:10.1080/15504263.2017.1390278 · Cited by 13
Negative Impacts of Psychiatric Medications on Oral Health: A Literature Review
Abed, H., Ezzat, Y., Alsaadawi, L., Almarzouki, R., Aboulkhair, R., Alqarni, A., & Sharka, R. M. (2023) · Cureus · doi:10.7759/cureus.49915 · Cited by 14
Tobacco Screening and Treatment of Patients With a Psychiatric Diagnosis, 2012–2015
Rogers, E., & Wysota, C. N. (2019) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2019.06.009 · Cited by 9
Addressing the arguments against implementation of smoke‐free policies in psychiatric facilities
Thomas, M., & RICHMOND, R. L. (2017) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12383 · Cited by 8
Trastornos del ánimo y trastornos por uso de sustancias: una comorbilidad compleja y frecuente
Ibáñez, C. F., Cáceresa, J., Brucher, R., & Daniel Seijas, B. (2020) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2020.02.005 · Cited by 72
Uncertainty Analysis in Intervention Impact on Health Inequality for Resource Allocation Decisions
Yang, F. B., Duarte, A., Walker, S., & Griffin, S. C. (2021) · Medical Decision Making · doi:10.1177/0272989x211009883 · Cited by 9
Smoking cessation in Asians: focus on varenicline
Xiao, D., Chu, S., & Wang, C. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s60785 · Cited by 7
Meta-analysis of the effects of adjuvant drugs in co-occurring bipolar and substance use disorder
Raduà, J., Fortea, L., Goikolea, J. M., Zorrilla, E. P., Bernardo, M., Arrojo, M., Cunill, R., Castells, X., Becoña, E., López‐Durán, A., et al. (2023) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2023.01.005 · Cited by 6
Evidence of the effectiveness and safety of first-line smoking cessation pharmacotherapy
Liakoni, E., & Benowitz, N. L. (2021) · European Respiratory Society eBooks · doi:10.1183/2312508x.10002420 · Cited by 6
Varenicline induced auditory hallucinations in a young female with bipolar disorder: a case report
Tsang, V. W. L., Bhanot, S., & Jia, L. (2023) · BMC Psychiatry · doi:10.1186/s12888-022-04348-6 · Cited by 6
Davies, K., Courtney, R. J., Summersby-Mitchell, M., Morell, R., Briggs, N., & Lappin, J. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221147206 · Cited by 8
Dickerson, F., Goldsholl, S., Yuan, C. T., Dalcin, A., Eidman, B., Minahan, E., Gennusa, J. V., Mace, E., Cullen, B., Evins, A. E., et al. (2023) · JMIR Research Protocols · doi:10.2196/44787 · Cited by 5
Wang, Y., Bos, J., Schuiling‐Veninga, C. C. M., Boezen, H. M., van Boven, J. F. M., Wilffert, B., & Hak, E. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-042417 · Cited by 5
Treatment of Tobacco Use Disorders in People with Mental Illness
Na, E., & Roh, S. (2015) · Journal of the Korean Society for Research on Nicotine and Tobacco · doi:10.25055/jksrnt.2015.6.2.78 · Cited by 4
González-Pinto, A. M., Goikolea, J. M., Zorrilla, E. P., Bernardo, M., Arrojo, M., Cunill, R., Castell, X., Becoña, E., López‐Durán, A., Torrens, M., et al. (2021) · Adicciones · doi:10.20882/adicciones.1528 · Cited by 9
Varenicline for Smoking Cessation in the Bipolar Patient
Tofler, I. R. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14lr09456 · Cited by 4
Fraile‐Μartinez, O., Montero, C. G., Ortega, M. A., Varaona, A., Gutiérrez-Rojas, L., Álvarez‐Mon, M., & Álvarez-Mon, M. Á. (2025) · Healthcare · doi:10.3390/healthcare13151783 · Cited by 5
Szerman, N., Carlos, P., Pinet, C., Martínez-Raga, J., Basurte, I., & Sáiz, P. A. (2022) · Actas Españolas de Psiquiatría · Cited by 5
Psychopharmacology of smoking cessation medications: focus on patients with mental health disorders
Castaldelli-Maia, J. M., de Oliveira, V. C., Irber, F. M., Blaas, I. K., Angerville, B., Martins-da-Silva, A. S., Gimenes, G. K., Campos, M. W., Torales, J. C., Ventriglio, A., et al. (2023) · International Review of Psychiatry · doi:10.1080/09540261.2023.2249084 · Cited by 4
Forrest, P. E., Brinson, A. J., Gannon, J. M., George, T. P., Perkins, K. A., & Chengappa, K. N. R. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000272 · Cited by 4
Self-citationSmoking cessation in people with serious mental illness
Evins, A. E., Cather, C., & Daumit, G. L. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30139-7 · Cited by 3
Seo, Y. B., Lee, H., Paek, Y., Lee, H., Lee, C. M., Lee, E. S., Kimm, H., An, H.-J., Bae, E.-J., Kim, J. S., et al. (2025) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e299 · Cited by 4
Efficacy of Varenicline for Smoking Cessation in Bipolar Disorder
Goldberg, J. F. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14com09103 · Cited by 2
Hudak, R., & Gannon, J. M. (2022) · Current clinical practice · doi:10.1007/978-3-030-98709-1_3 · Cited by 2
Yang, F. B., Angus, C., Duarte, A., Gillespie, D., Sculpher, M., Walker, S., & Griffin, S. C. (2021) · RePEc: Research Papers in Economics · Cited by 2
Risk Factors for Natural Cause Mortality in Bipolar Disorder
Dickerson, F., Khan, S., Origoni, A. E., Rowe, K. C., Katsafanas, E., Mukhtar, F., & Yolken, R. H. (2026) · Bipolar Disorders · doi:10.1111/bdi.70092 · Cited by 1
Dickerson, F., Fink, T., Goldsholl, S., Dalcin, A., Eidman, B., Yuan, C. T., Gennusa, J. V., Cather, C., Evins, A. E., Wang, N., et al. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241309678 · Cited by 1
Treatment of Tobacco Use Disorder and Mood Disorders in Adolescents
Witt, D. R., & Patten, C. A. (2018) · Current Addiction Reports · doi:10.1007/s40429-018-0216-9 · Cited by 2
Radchenko, E. V., Sykhovskaya, O. A., Леонидович, Г. Т., Колбин, А. С., & Smirnova, M. A. (2018) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf16419-32 · Cited by 3
Dickerson, F., Goldsholl, S., Yuan, C. T., Dalcin, A., Eidman, B., Minahan, E., Gennusa, J. V., Mace, E., Cullen, B., Evins, A. E., et al. (2022) · doi:10.2196/preprints.44787
Troubles bipolaires et comorbidités addictives
Roméo, B., & Benyamina, A. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-77180-4.00032-9
Tsang, V. W. L., Bhanot, S., & Jia, L. (2024) · Figshare · doi:10.6084/m9.figshare.26558954
Dr Chengappa and Colleagues Reply
Chengappa, K. N. R., Perkins, K. A., Brar, J. S., Turkin, S. R., Levine, M. D., & George, T. P. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14lr09456a
Self-citation
Metadata
- Authors
- Chengappa, K. N. R., Perkins, K. A., Brar, J. S., Schlicht, P. J., Turkin, S. R., Hetrick, M. L., Levine, M. D., & George, T. P.
- Affiliations
- University of Pittsburgh Medical Center (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-06-10
- Volume
- 75
- Issue
- 07
- Pages
- 765-772
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2089345569
- Cited by
- 86
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 11 · 2022: 4 · 2021: 9 · 2020: 5 · 2019: 7 · 2018: 7 · 2017: 9 · 2016: 9 · 2015: 18 · 2014: 1
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R21MH087928)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- varenicline, smoking cessation, bipolar disorder, nicotine dependence, neuropsychiatric adverse effects, suicidal ideation, smoking abstinence, smoking cessation counseling, expired carbon monoxide, mood stabilizers
- MeSH terms
- Varenicline, Adult, Benzazepines, Bipolar Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Smoking, Comorbidity, Smoking Cessation, Treatment Outcome, Nicotinic Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.